9 Biotechnology Stocks to Buy Now

Advertisement

The grades of nine biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, Stemline Therapeutics, Inc. (STML) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. For more information, get Portfolio Grader’s complete analysis of STML stock.

Pharmacyclics, Inc.’s (PCYC) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. Shares of the stock have been changing hands at an unusually rapid pace, three times the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of PCYC stock.

Acorda Therapeutics, Inc.’s (ACOR) ratings are looking better this week, moving up to a B from last week’s C. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

This is a strong week for Northwest Biotherapeutics, Inc. (NWBO). The company’s rating climbs to B from the previous week’s C. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.

MediciNova, Inc. (MNOV) boosts its rating from a B to an A this week. Medicinova acquires, develops, and commercializes small molecule therapeutics. For more information, get Portfolio Grader’s complete analysis of MNOV stock.

BioMarin Pharmaceutical (BMRN) gets a higher grade this week, advancing from a C last week to a B. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.

Seattle Genetics, Inc. (SGEN) earns a B this week, jumping up from last week’s grade of C. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.

This week, Ambit Biosciences Corp. (AMBI) pushes up from a C to a B rating. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Amgen (AMGN) shows solid improvement this week. The company’s rating rises from a B to an A. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2014/10/9-biotechnology-stocks-to-buy-now-stml-pcyc-acor-4/.

©2024 InvestorPlace Media, LLC